泽泻-白术药对及其活性成分防治动脉粥样硬化研究进展  

Research progress of Alisma orientale-Atractylodes macrocephala herb pair and its active ingredients in prevention and treatment of atherosclerosis

作　　者：张匣 邵欣欣 刘青芝 弭志成 母伟林 胡亚洁[1] 陈聪[1] ZHANG Xia;SHAO Xinxin;LIU Qingzhi;MI Zhicheng;MU Weilin;HU Yajie;CHEN Cong(Shandong University of Traditional Chinese Medicine,Jinan 250355,China)

机构地区：[1]山东中医药大学,山东济南250355

出　　处：《中草药》2024年第16期5735-5746,共12页Chinese Traditional and Herbal Drugs

基　　金：山东省自然科学基金资助项目(ZR2017LH062);山东省中医药科技项目(M-2022144);中药配方颗粒现代化生产线优化项目。

摘　　要：动脉粥样硬化(atherosclerosis,AS)是一种脂质驱动的免疫炎症性疾病,可引发冠心病、脑卒中等严重的心脑血管疾病,具有全球高发病率和高致死率的特点。中医认为脾运失健、痰浊阻滞是AS发生发展的内在机制,健脾化浊法为其主要治则。泽泻-白术为具有健脾祛湿功效的经典药对,已有研究表明该药对及其活性成分具有明确的防治AS作用,通过对泽泻-白术药对及其活性成分防治AS作用机制相关文献进行梳理,从保护血管内皮细胞(endothelial cells,ECs)功能、抑制巨噬细胞泡沫化、调节巨噬细胞M1/M2极化平衡、抑制血管平滑肌细胞(vascular smooth muscle cells,VSMCs)增殖、表型转化、延缓血管平滑肌细胞迁移、抑制血小板活化和聚集、抗炎、调节脂质代谢、影响与AS相关的风险因素等角度对其防治AS作用机制进行综述,以期为该药对防治AS的临床应用和功能性食品及药品领域的开发和综合利用提供理论依据。Atherosclerosis(AS)is a lipid-driven immunoinflammatory disease which can cause serious cardiovascular and cerebrovascular diseases such as coronary heart disease and stroke.It has the characteristics of high incidence and mortality in the world.Traditional Chinese medicine theory believes that Piyunshijian and Tanzhuozuzhi are the internal mechanisms of the occurrence and development of AS,invigorating spleen and resolving turbidity are its main therapeutic principles.Alisma orientale-Atractylodes macrocephala herb pair is a classic medicine pair which has the effect of invigorating spleen and dispelling dampness,studies have shown that this pair and its active ingredients have clear anti-AS effects.In this paper,we have reviewed the literature on the anti-AS mechanism of the A.orientale-A.macrocephala herb pair and its active ingredients,and reviewed its anti-AS mechanism of action from the aspects of protecting vascular endothelial cell function,inhibiting macrophage foaming,regulating macrophage M1/M2 polarization balance,inhibiting vascular smooth muscle cell proliferation and phenotypic transformation,delaying vascular smooth muscle cell migration,inhibiting platelet activation and aggregation,anti-inflammatory,regulating blood lipid levels,and affecting risk factors related to AS,etc.,in order to provide a theoretical basis for the clinical application of the pair in the prevention and treatment of AS and the development and comprehensive utilization of functional food and drugs.

关 键 词：泽泻-白术药对 泽泻汤 动脉粥样硬化 23-乙酰泽泻醇B 24-乙酰泽泻醇A 泽泻醇B 泽泻醇A 白术内酯类 白术多糖 

分 类 号：R286.2[医药卫生—中药学]